The number of adults diagnosed with diabetes has more than quadrupled since 1990 and now stands above 800 million, according ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

Sharon Osbourne sparked surgery concern once again this week as she stepped out in LA on Wednesday with a noticeably more ...

The new weight-loss drugs have created “a hope and optimism ... by at least 5 percent in most participants after 56 weeks. A 2022 trial of 201 teens aged 12 to 18 reported a higher treatment ...

As revenues fall in diabetes treatments, has the industry found a new revenue driver in weight-loss treatments ... the FDA for type 2 diabetes in May 2022, and, ahead of any additional approval ...

Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new ...

Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss? There’s been lots of attention ... over the course of a 68-week treatment. A 2022 study sponsored by Eli Lilly followed more than ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Oct 30 (Reuters) - The lowest dose of Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drug ... on the U.S. Food and Drug Administration's shortage list since early 2022.

Amid the growing use of weight loss medications, a new study has raised concerns about declining skeletal muscle health caused by the popular drugs. In a recent commentary published in The Lancet ...